Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2623
Gene Symbol: GATA1
GATA1
0.100 GeneticVariation disease BEFREE Importantly, alterations in any of those GATA1 regulatory checkpoints have been recognized as an important cause of hematological disorders such as dyserythropoiesis (with or without thrombocytopenia), β-thalassemia, Diamond-Blackfan anemia, myelodysplasia, or leukemia. 31769197 2020
Entrez Id: 2120
Gene Symbol: ETV6
ETV6
0.100 Biomarker disease BEFREE The modification of this translocation may lead to reducing effects of the fusion gene's damaging and the dosage compensation related to ETV6 and RUNX1 genes and subsequently reduce the effects of leukemia. 31602594 2020
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.100 Biomarker disease BEFREE Emodin and AZT synergistically inhibit the proliferation and induce the apoptosis of leukemia K562 cells through the EGR1 and the Wnt/β‑catenin pathway. 31746437 2020
Entrez Id: 7852
Gene Symbol: CXCR4
CXCR4
0.100 Biomarker disease BEFREE Moreover, blocking the CCL3-CCR1/CCR5 and CXCL12-CXCR4 axes inhibited Treg accumulation in the LHME and delayed leukemia progression. 31669202 2020
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Mass cytometry data revealed that BCL2 protein is enriched in leukemia stem/progenitor cells, primarily in venetoclax-sensitive samples and that cobimetinib suppressed cytokine-induced pERK and pS6 signaling pathways. 31123034 2020
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE Compound 7a notably inhibited the expression and activity of PIM kinases, as evidenced by reduced B‑cell lymphoma‑2 (Bcl‑2)‑associated death promoter phosphorylation at Ser112. 31789392 2020
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Tet methylcytosine dioxygenase (Tet2), B-cell lymphoma 2 (Bcl2), and solute carrier family 23 member 2 (Slc23a2) are the major target genes in the treatment of leukemia and are relevant to vitamin C. 31467227 2020
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.100 AlteredExpression disease BEFREE We show that exposure of leukemia cells to daunorubicin activated an integrated stress response-like transcriptional program to induce ABCB1 through remodeling and activation of an ATF4-bound, stress-responsive enhancer. 31770110 2020
Entrez Id: 4629
Gene Symbol: MYH11
MYH11
0.100 Biomarker disease BEFREE In summary, reduction of Gata2 activity affects mutational dynamics of leukemia with delayed leukemia onset in Cbfb-MYH11 knockin mice, but paradoxically results in a more aggressive leukemia phenotype, which may be correlated with leukemia relapse or poor prognosis in human patients. 31624376 2020
Entrez Id: 80150
Gene Symbol: ASRGL1
ASRGL1
0.100 Biomarker disease BEFREE Taken together, the results showed that chemical modification with carboxymethyl dextran brings about improvement of biochemical properties through several changes in the structural attributes of l-asparaginase and might enhance its applicability in the treatment of childhood leukemia. 31821805 2020
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE The characteristic high-level expression of BCL2 in CLL that can enhance leukemia-cell survival has now become an Achilles heel targeted by clinically effective drugs such as venetoclax. 31764118 2020
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.100 Biomarker disease BEFREE In addition, this inhibitor may serve as a promising therapeutic strategy for MLL leukemia by targeting CBP BrD protein. 31253937 2020
Entrez Id: 6776
Gene Symbol: STAT5A
STAT5A
0.100 AlteredExpression disease BEFREE High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. 31123029 2020
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.100 Biomarker disease BEFREE There is a high unmet need to identify safer and more potent therapies for MLL-rearranged (MLL-r) leukemia that can be combined with established chemotherapeutics to decrease treatment-related toxicities. 31325323 2020
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker disease BEFREE The modification of this translocation may lead to reducing effects of the fusion gene's damaging and the dosage compensation related to ETV6 and RUNX1 genes and subsequently reduce the effects of leukemia. 31602594 2020
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.100 Biomarker disease BEFREE Here, we studied the distribution and characteristics of Tregs in the LHME, investigated the effects of Treg ablation on leukemia progression, explored the mechanisms leading to Treg accumulation, and studied whether blocking Treg migration to the LHME delayed leukemia progression in MLL-AF9-induced mouse acute myeloid leukemia (AML) models using wildtype (WT) and Foxp3<sup>DTR/GFP</sup> mice. 31669202 2020
Entrez Id: 4851
Gene Symbol: NOTCH1
NOTCH1
0.100 AlteredExpression disease BEFREE Consistent with this hypothesis, mice transplanted with T-cells co-expressing NOTCH1 and NRARP develop leukemia later than mice transplanted with T-NOTCH1 cells. 31586130 2020
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE Control of graft-versus-host disease with rabbit anti-thymocyte globulin, rituximab, and bortezomib in TCRαβ/CD19-depleted graft transplantation for leukemia in children: a single-center retrospective analysis of two GVHD-prophylaxis regimens. 31680369 2020
Entrez Id: 4869
Gene Symbol: NPM1
NPM1
0.100 GeneticVariation disease BEFREE Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias. 30919505 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 Biomarker disease BEFREE After 6 months of monitoring, leukemia cell contamination was assessed in ovarian grafts and mouse organs by histology, PCR (presence of mouse mtDNA and absence of p53 were together considered a negative result for the presence of human cells) and detection of immunoglobulin monoclonality and specific ALL markers if present in the patient.In experiment 2, a series of 22 immunodeficient female mice was injected with specific doses of the leukemia cell line RCH-ACV (103 - 5 × 106, n = 4/group) to assess the engraftment competence of the SCID model. 31339993 2019
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.100 Biomarker disease BEFREE Furthermore, the miR-124 mimic obviously upregulated glycogen synthase kinase 3β (GSK-3β) while downregulating β-catenin, T cell transcription factor 4 (TCF-4) and leukemia enhancer factor 1 (LEF-1). 30740945 2019
Entrez Id: 4609
Gene Symbol: MYC
MYC
0.100 Biomarker disease BEFREE Treatment with the DPY30-binding peptides significantly inhibited the growth of MLL-rearranged leukemia and other MYC-dependent hematologic cancer cells. 31251903 2019
Entrez Id: 6776
Gene Symbol: STAT5A
STAT5A
0.100 Biomarker disease BEFREE Peroxisome proliferator-activated receptor-γ (PPARγ) agonist pioglitazone downregulates signal transducer and activator of transcription 5 (STAT5) and in combination with imatinib induces complete molecular response in imatinib-refractory patients by eroding leukemia stem cells. 31371410 2019
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation disease BEFREE AML1-ETO (AE) is a fusion transcription factor, generated by the t(8;21) translocation, that functions as a leukemia promoting oncogene. 31664040 2019
Entrez Id: 3197
Gene Symbol: HOXA@
HOXA@
0.100 AlteredExpression disease BEFREE We found that SOCS5 was differentially expressed in primary T-ALL and its expression levels were lowered in HOXA-deregulated leukemia harboring KMT2A gene rearrangements. 30974024 2019